Advanced search×

Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer.

Anticancer Res 30(9):3373-9 (2010) PMID 20944111

BACKGROUND: In this study, different variants of the anti-PSMA single-chain antibody fragment (scFv) D7 were cloned, varying in linker type, position of hexahistidine tags and VH-VL orientation. From these scFv, Pseudomonas exotoxin A-based immunotoxins were constructed and their biological activities against prostate cancer cells were compared. MATERIALS AND METHODS: Binding of the constructs to PSMA-expressing prostate cancer cells was determined by flow cytometry. ADP-ribosyltransferase activity was analysed and cytotoxicity was measured with WST-1 assays. RESULTS: Different linker types did not influence the characteristics of the scFv or immunotoxins. The addition of an N-terminal hexahistidine-tag, however, resulted in decreased expression, binding and cytotoxicity. scFv in VH-VL orientation showed the highest expression and binding, whereas immunotoxins in VL-VH orientation exhibited the best binding and cytotoxicity. CONCLUSION: The present study showed how structure influences the characteristics of scFv and immunotoxins. It is therefore suggested that for each individual construct the optimal structure has to be determined separately.

Version: za2963e q8za0 q8zb8 q8zc5 q8zdc q8zed q8zfb q8zgc

Similar articles you may find interesting…

  1. Myeloid sarcoma presenting as an anterior mediastinal mass invading the pericardium: Serial Imaging With F-18 FDG PET/CT.

    Clin Nucl Med 35(9):706-9 (2010) PMID 20706048

    Myeloid sarcoma is a tumor formed by extramedullary accumulation of myeloblasts or immature myeloid cells. These tumors can develop in lymphoid organs, bone, skin, soft tissue, and other organs, and may precede or occur concurrently with acute myeloid leukemia. This is a case of a 42-year-old man wh...
  2. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.

    Cancer Immunol Immunother 57(1):43-52 (2008) PMID 17579857

    The PSMAxCD3 diabody bears the potential for facilitating immunotherapy of prostate cancer and for the elimination of minimal residual disease....
  3. [Evaluation of three in-vitro refolding methods for human-derived anti-CTLA4 scFv expressed in E. coli].

    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 23(2):388-91 (2006) PMID 16706373

    To evaluate the efficiency of three in vitro refolding methods for a humanized single-chain Fv antibody against human CTLA4(CD152) expressed in E. coli, the denatured and purified inclusion bodies (IBS) were refolded by dilution, dialysis and in situ refolding via Immobilized Metal-Ion-Affinity Chro...